donepezil has been researched along with indocyanine green in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Akiyama, T; Arikawa, M; Furihata, M; Handa, T; Kakinuma, Y; Katare, RG; Sato, T | 1 |
1 review(s) available for donepezil and indocyanine green
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for donepezil and indocyanine green
| Article | Year |
|---|---|
Donepezil, an acetylcholinesterase inhibitor against Alzheimer's dementia, promotes angiogenesis in an ischemic hindlimb model.
Topics: Acetylcholine; Alzheimer Disease; Animals; Caspase 3; Caspase 7; Cholinesterase Inhibitors; Donepezil; Endothelial Cells; Hindlimb; Humans; Hypoxia; Indans; Indocyanine Green; Ischemia; Mice; Mice, Knockout; Microscopy, Fluorescence; Neovascularization, Pathologic; Piperidines; Vascular Endothelial Growth Factor A | 2010 |